Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $44.05 USD
Change Today +3.56 / 8.79%
Volume 416.0K
TTPH On Other Exchanges
Symbol
Exchange
Berlin
As of 11:19 AM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

tetraphase pharmaceuticals i (TTPH) Snapshot

Open
$41.79
Previous Close
$40.49
Day High
$44.45
Day Low
$41.79
52 Week High
07/15/15 - $52.90
52 Week Low
08/28/14 - $12.51
Market Cap
1.6B
Average Volume 10 Days
448.6K
EPS TTM
$-2.62
Shares Outstanding
36.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for TETRAPHASE PHARMACEUTICALS I (TTPH)

tetraphase pharmaceuticals i (TTPH) Related Bloomberg News

View More Bloomberg News

tetraphase pharmaceuticals i (TTPH) Related Businessweek News

No Related Businessweek News Found

tetraphase pharmaceuticals i (TTPH) Details

Tetraphase Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multi-drug resistant infections. Its lead product candidate includes eravacycline, an intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant Gram-negative infections. The company is conducting a Phase 3 clinical trial of eravacycline with intravenous administration for the treatment of complicated intra-abdominal infections; and a second Phase 3 clinical trial of eravacycline for the treatment of complicated urinary tract infections with intravenous-to- oral transition therapy. It is also developing TP-271, a preclinical compound for respiratory diseases caused by bacterial biothreat pathogens; and TP-6076, a preclinical Gram-negative program for multidrug-resistant Gram-negative infections. The company was founded in 2006 and is headquartered in Watertown, Massachusetts.

55 Employees
Last Reported Date: 03/6/15
Founded in 2006

tetraphase pharmaceuticals i (TTPH) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $420.0K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $318.0K
Chief Operating Officer
Total Annual Compensation: $311.2K
Chief Medical Officer
Total Annual Compensation: $360.0K
Compensation as of Fiscal Year 2014.

tetraphase pharmaceuticals i (TTPH) Key Developments

Tetraphase Pharmaceuticals Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Tetraphase Pharmaceuticals reported earnings results for the second quarter of 2015. For the second quarter of 2015, the company reported a net loss of $26 million or $0.72 per share compared to a net loss of $18.5 million or $0.71 per share for the same period in 2014. Revenues during the second quarter of 2015 were $3.3 million compared to $1.3 million for the same period in 2014. Revenues for each period consisted of contract and grant revenue under its U.S. government awards for the development of its compounds for the treatment of diseases called by -- caused by bacterial biothreat pathogens and for certain infections caused by life-threatening multidrug-resistant bacteria. This increase was primarily due to the scope and timing of activities related to its BARDA contract conducted during the second quarter of 2015. Loss from operations was $26.053 million against $18.185 million a year ago. For the six months, the company reported revenues of $6.359 million against $3.732 million a year ago. Loss from operations was $46.814 million against $3.732 million a year ago. Net loss was $47.030 million or $1.38 per basic and diluted share against $31.986 million or $1.24 per basic and diluted share a year ago.

Tetraphase Pharmaceuticals, Inc. to Report Q2, 2015 Results on Aug 05, 2015

Tetraphase Pharmaceuticals, Inc. announced that they will report Q2, 2015 results at 5:00 PM, Eastern Standard Time on Aug 05, 2015

Tetraphase Pharmaceuticals, Inc., Q2 2015 Earnings Call, Aug 05, 2015

Tetraphase Pharmaceuticals, Inc., Q2 2015 Earnings Call, Aug 05, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TTPH:US $44.05 USD +3.56

TTPH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TTPH.
View Industry Companies
 

Industry Analysis

TTPH

Industry Average

Valuation TTPH Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 122.8x
Price/Book 6.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 102.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TETRAPHASE PHARMACEUTICALS I, please visit www.tphase.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.